Close Menu

NEW YORK – With its recent acquisition of Finnish molecular diagnostics firm Blueprint Genetics, Quest Diagnostics is looking to expand and improve its genetic testing portfolio.

The lab company was particularly interested in Blueprint's informatics capabilities, which Carrie Eglinton Manner, Quest's senior vice president of Advanced Diagnostics, said would enhance its existing genetic test offerings by improving variant interpretation and reporting.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.